» Articles » PMID: 10984541

Erythropoietin Crosses the Blood-brain Barrier to Protect Against Experimental Brain Injury

Overview
Specialty Science
Date 2000 Sep 14
PMID 10984541
Citations 404
Authors
Affiliations
Soon will be listed here.
Abstract

Erythropoietin (EPO), recognized for its central role in erythropoiesis, also mediates neuroprotection when the recombinant form (r-Hu-EPO) is directly injected into ischemic rodent brain. We observed abundant expression of the EPO receptor at brain capillaries, which could provide a route for circulating EPO to enter the brain. In confirmation of this hypothesis, systemic administration of r-Hu-EPO before or up to 6 h after focal brain ischemia reduced injury by approximately 50-75%. R-Hu-EPO also ameliorates the extent of concussive brain injury, the immune damage in experimental autoimmune encephalomyelitis, and the toxicity of kainate. Given r-Hu-EPO's excellent safety profile, clinical trials evaluating systemically administered r-Hu-EPO as a general neuroprotective treatment are warranted.

Citing Articles

Epoetin alfa has a potent anxiolytic effect on naive female rats.

Caliskan H, Kocak S, Gunes E BMC Pharmacol Toxicol. 2025; 26(1):18.

PMID: 39876022 PMC: 11773716. DOI: 10.1186/s40360-025-00845-y.


Erythropoietin to Treat Spinal Cord Injury: Evaluation of Different Doses and Magnitudes of Trauma in Rats.

Barros A, Santos G, Marcon R, Cristante A Global Spine J. 2024; :21925682241306106.

PMID: 39652832 PMC: 11629366. DOI: 10.1177/21925682241306106.


Darbepoetin alpha has an anxiolytic and anti-neuroinflammatory effect in male rats.

Caliskan H, Onal D, Nalcaci E BMC Immunol. 2024; 25(1):75.

PMID: 39523336 PMC: 11552158. DOI: 10.1186/s12865-024-00665-5.


Chronic Administration of Recombinant Human Erythropoietin Induces Angiogenesis in Healthy Mouse Brain.

Pagonopoulou O, Papadatou V, Tologkos S, Efthimiadou A, Maria L Cureus. 2024; 16(9):e68362.

PMID: 39355466 PMC: 11443503. DOI: 10.7759/cureus.68362.


Clinical Management in Traumatic Brain Injury.

Yan A, Torpey A, Morrisroe E, Andraous W, Costa A, Bergese S Biomedicines. 2024; 12(4).

PMID: 38672137 PMC: 11048642. DOI: 10.3390/biomedicines12040781.


References
1.
Egrie J, Browne J, Lai P, Lin F . Characterization of recombinant monkey and human erythropoietin. Prog Clin Biol Res. 1985; 191:339-50. View

2.
Juul S, Anderson D, Li Y, Christensen R . Erythropoietin and erythropoietin receptor in the developing human central nervous system. Pediatr Res. 1998; 43(1):40-9. DOI: 10.1203/00006450-199801000-00007. View

3.
Pardridge W, Eisenberg J, Yang J . Human blood-brain barrier transferrin receptor. Metabolism. 1987; 36(9):892-5. DOI: 10.1016/0026-0495(87)90099-0. View

4.
Duffy K, Pardridge W, Rosenfeld R . Human blood-brain barrier insulin-like growth factor receptor. Metabolism. 1988; 37(2):136-40. DOI: 10.1016/s0026-0495(98)90007-5. View

5.
Broadwell R, Balin B, Salcman M . Transcytotic pathway for blood-borne protein through the blood-brain barrier. Proc Natl Acad Sci U S A. 1988; 85(2):632-6. PMC: 279605. DOI: 10.1073/pnas.85.2.632. View